Autopsy report · NCT00931606

Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)

“administrative reasons (slow patient enrollment)”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 30 participants enrolled.
• Results were posted on the registry 12 years 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Chemotherapy Induced Anemia

Interventions

Sotatercept; Placebo

Participants

30

Sites

35

Countries

Russia, United States

Trials that died the same way

• Use of 3M Cavilon Advanced Skin Protectant in the Management of Damaged Skin Around an Ostomy, Drain or Fistula
  “Slow enrollment of patients” (85% match in meaning)
• CNP-201 in Subjects With Peanut Allergy
  “Lagging Enrollment and Administrative Reasons” (79% match in meaning)
• The Impact of Nebivolol Versus Metoprolol on Quality of Life
  “due to slow enrollment” (79% match in meaning)
• A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
  “Slow enrollment.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.